{"meta":{"query_hash":"59bc5d409406","filters":{"venue":"PharmaDeals Review"},"cohort_total":12,"direct_labels_cover":0,"predictions_cover":12,"exported":12,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/59bc5d409406","api":"https://metacan.xera.ac/api/v1/cohort?venue=PharmaDeals+Review"},"results":[{"id":"W128615782","doi":"10.3833/pdr.v2012i3.1692","title":"Actelion Gains Rights to Auxilium’s Xiaflex® in Canada, Australia, Brazil and Mexico","year":2012,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"Dupuytren's Contracture and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Political science; Medicine; Management; Family medicine; Economics","score_opus":0.06126565779868655,"score_gpt":0.39629554123680627,"score_spread":0.33502988343811974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W128615782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.76442933,0.21290667,0.000006428249,0.013953676,0.00046618137,0.00230064,0.00005321454,0.000040366056,0.0058435216],"genre_scores_gemma":[0.96432394,0.021555377,0.00009664517,0.012141695,0.00014207161,0.000073164585,0.000041219566,0.000015801466,0.0016100849],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99854106,0.000077709905,0.00038232474,0.00024069626,0.0002655651,0.0004926573],"domain_scores_gemma":[0.9989688,0.000057727313,0.00007906989,0.00024052928,0.00003776892,0.0006161112],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00023116104,0.00023559049,0.0006076353,0.00007696345,0.0000407678,0.000008577876,0.00007281642,0.000041783227,0.0009267722],"category_scores_gemma":[0.00004250035,0.00016907687,0.000062678606,0.0002303347,0.000013664248,0.00016786969,0.000029766137,0.00017881126,0.00027013838],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023997892,0.0010299237,0.44413173,0.006633951,0.00045624224,0.0012932825,0.0005337812,0.0000015084615,0.0019068893,0.0003857923,0.2858062,0.25758073],"study_design_scores_gemma":[0.0013835247,0.00005611882,0.23658064,0.0029323932,0.00043710912,0.00017927372,0.000005244939,0.0000018650613,0.0029353746,0.00002189267,0.75522363,0.00024294978],"about_ca_topic_score_codex":0.24531859,"about_ca_topic_score_gemma":0.2033988,"teacher_disagreement_score":0.4694174,"about_ca_system_score_codex":0.00031992412,"about_ca_system_score_gemma":0.00015442506,"threshold_uncertainty_score":0.9999865},"labels":[],"label_agreement":null},{"id":"W131397720","doi":"10.3833/pdr.v2011i5.1473","title":"Mundipharma Gains Commercialisation Rights to Allos Therapeutics’ Folotyn® Outside of North America","year":2011,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Business","score_opus":0.2517164448078097,"score_gpt":0.43659777920550064,"score_spread":0.18488133439769094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W131397720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.46606842,0.3126324,0.002458244,0.025703566,0.001352227,0.026133008,0.00037799313,0.0007798936,0.16449423],"genre_scores_gemma":[0.71312714,0.24095081,0.0018998804,0.041142974,0.00037821836,0.0003931728,0.00016090537,0.00011313144,0.0018337463],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99759823,0.00034126357,0.0007184636,0.00033719538,0.00057482615,0.00042999533],"domain_scores_gemma":[0.9984167,0.000113861766,0.0002280344,0.0006128134,0.00028241225,0.00034614815],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00052239053,0.00025928387,0.0008631024,0.00016420969,0.00007643428,0.0000072225644,0.000332618,0.00004142466,0.010020165],"category_scores_gemma":[0.000047816924,0.00020523388,0.00028647514,0.00061892776,0.00012390866,0.000095241674,0.00008293985,0.0002889283,0.00057381],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00093346264,0.0012977044,0.017226927,0.0063941623,0.001077192,0.00009434475,0.003928805,0.0000015434417,0.04361036,0.00013720799,0.023139808,0.9021585],"study_design_scores_gemma":[0.0014000043,0.00052117265,0.015515103,0.0016524439,0.000731422,0.000032856624,0.000015513348,0.0000321049,0.023963671,0.00007923141,0.95574725,0.00030924342],"about_ca_topic_score_codex":0.00045927477,"about_ca_topic_score_gemma":0.000047164613,"teacher_disagreement_score":0.9326074,"about_ca_system_score_codex":0.00009734927,"about_ca_system_score_gemma":0.000092646515,"threshold_uncertainty_score":0.99088484},"labels":[],"label_agreement":null},{"id":"W150401912","doi":"10.3833/pdr.v2011i6.1485","title":"Boehringer Ingelheim Licenses Zealand Pharma’s Drug Candidates for Type 2 Diabetes and Obesity","year":2011,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"Pharmacology and Obesity Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Milestone; Type 2 diabetes; Payment; Obesity; Quarter (Canadian coin); Business; Diabetes mellitus; Internal medicine; Finance; Endocrinology; Geography","score_opus":0.08240199183654418,"score_gpt":0.3650932836274937,"score_spread":0.28269129179094954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W150401912","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.644533,0.3512621,0.0000020343343,0.0013771812,0.0002324086,0.0014706147,0.00003269949,0.00009295723,0.0009970007],"genre_scores_gemma":[0.6315562,0.3558418,0.00053116685,0.010264812,0.00018512308,0.00021317379,0.000065124346,0.00003341663,0.0013091835],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99877125,0.0000895239,0.00031423874,0.00033114484,0.00011040368,0.00038345286],"domain_scores_gemma":[0.99916625,0.00013459535,0.00012334817,0.00017731302,0.00011715775,0.0002813552],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041536547,0.00024716338,0.00064036145,0.000058044247,0.00012834734,0.000008584484,0.000094958006,0.000049430037,0.0008761882],"category_scores_gemma":[0.00007672461,0.00018972575,0.000113040434,0.00012763403,0.00008269593,0.00012071748,0.000058225545,0.00016536574,0.00011202497],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007801456,0.0018423869,0.5823645,0.022886107,0.00179304,0.00013818486,0.0017189801,8.24894e-8,0.009648404,0.00010345102,0.34292606,0.03579867],"study_design_scores_gemma":[0.008326405,0.0007671262,0.09135862,0.006354763,0.008431867,0.00016186104,0.0000280749,0.000084414794,0.17583409,0.00035343863,0.7074061,0.00089324074],"about_ca_topic_score_codex":0.000025322995,"about_ca_topic_score_gemma":0.000004115886,"teacher_disagreement_score":0.49100587,"about_ca_system_score_codex":0.00003671734,"about_ca_system_score_gemma":0.00006172236,"threshold_uncertainty_score":0.95936465},"labels":[],"label_agreement":null},{"id":"W1578951455","doi":"10.3833/pdr.v2013i4.1921","title":"Lundbeck and Otsuka Expand Alliance with Deal for Late-Stage Alzheimer’s Disease Programme","year":2013,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"Science, Research, and Medicine","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Alliance; Product (mathematics); Disease; Political science; Business; Medicine; Internal medicine","score_opus":0.13993692469553828,"score_gpt":0.4159867448974022,"score_spread":0.27604982020186397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1578951455","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09179043,0.86950386,0.00023856983,0.025881683,0.00009302337,0.011032311,0.000035054225,0.0001296343,0.0012954384],"genre_scores_gemma":[0.17788449,0.77297586,0.0055319625,0.028291758,0.0006578936,0.0050417446,0.00019236919,0.00010574795,0.009318195],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980415,0.00005121857,0.0003297884,0.00044540127,0.00048640626,0.0006456787],"domain_scores_gemma":[0.99800676,0.000110873065,0.000106398395,0.00031227962,0.00024433047,0.0012193517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066110794,0.0002206787,0.0005515865,0.000044822038,0.000106200394,0.000039130588,0.00015212386,0.000029632392,0.0007392197],"category_scores_gemma":[0.00017736111,0.00013379504,0.000084445026,0.00027980722,0.0002589901,0.00021587563,0.000040278686,0.00017113896,0.00013003702],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055348553,0.0005065628,0.03125897,0.030179791,0.00033420484,0.00020311889,0.00029794808,0.0000014353705,0.0018673455,0.0003074091,0.07619192,0.8582978],"study_design_scores_gemma":[0.0048625143,0.0007128756,0.016371248,0.008830935,0.0011655617,0.00004751054,0.00006702082,0.00077351887,0.0006141427,0.00006977984,0.96610945,0.00037546235],"about_ca_topic_score_codex":0.00006668106,"about_ca_topic_score_gemma":0.000004948575,"teacher_disagreement_score":0.8899175,"about_ca_system_score_codex":0.000024553174,"about_ca_system_score_gemma":0.00023283015,"threshold_uncertainty_score":0.80939376},"labels":[],"label_agreement":null},{"id":"W202721108","doi":"10.3833/pdr.v2011i8.1518","title":"Bayer Licenses Regional Rights to Trius Therapeutics’ Phase III Antibiotic for Serious Gram-Positive Infections","year":2011,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"China; Latin Americans; Medicine; International trade; Political science; Business; Law","score_opus":0.20075728967151268,"score_gpt":0.38651749375098643,"score_spread":0.18576020407947375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W202721108","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13221096,0.60074824,0.015413489,0.045798536,0.0048426082,0.020525659,0.006681586,0.0006921367,0.17308679],"genre_scores_gemma":[0.7765279,0.1392045,0.0011192099,0.08106887,0.00057288195,0.00042156578,0.00009892743,0.000095372096,0.00089079066],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99791235,0.000039588624,0.0009631228,0.0005301001,0.00003269618,0.00052214117],"domain_scores_gemma":[0.9987439,0.0001286626,0.0003685088,0.00033356302,0.00007806227,0.0003473219],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00054371654,0.00029458865,0.0008335509,0.0002003308,0.00022472888,0.000049155668,0.00030380543,0.000070519105,0.0011350551],"category_scores_gemma":[0.000038668906,0.0003009978,0.00037274428,0.0003244164,0.00006486375,0.0002267457,0.000053272353,0.00018768213,0.0013885911],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00079316803,0.0053813867,0.0011047038,0.003678282,0.0023312415,0.00003615201,0.0026855583,0.000015715228,0.0006814833,0.7699059,0.121351786,0.09203458],"study_design_scores_gemma":[0.002414549,0.0002743804,0.00025649587,0.00029012884,0.00014219612,0.000031915646,0.0000027524557,0.0002660568,0.001192837,0.013946181,0.9807003,0.00048218045],"about_ca_topic_score_codex":0.00019283971,"about_ca_topic_score_gemma":0.000015395704,"teacher_disagreement_score":0.85934854,"about_ca_system_score_codex":0.00010169739,"about_ca_system_score_gemma":0.00003599252,"threshold_uncertainty_score":0.9999442},"labels":[],"label_agreement":null},{"id":"W205713971","doi":"10.3833/pdr.v2012i1.1646","title":"Prestige Brands Agrees to Buy GSK’s Non-Core North American OTC Brands","year":2012,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"Diverse Perspectives in Modern Studies","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Divestment; Prestige; Business; Cash; Shareholder; Database transaction; Order (exchange); Hard core; Advertising; Commerce; Finance; Corporate governance","score_opus":0.09439475362979195,"score_gpt":0.32693237253849217,"score_spread":0.23253761890870023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W205713971","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17982057,0.68142706,0.0023246766,0.0058100186,0.0016986904,0.0025486317,0.0009019874,0.0002405473,0.12522784],"genre_scores_gemma":[0.80252314,0.18989977,0.0007874566,0.0049197744,0.0004566776,0.00019200807,0.000017559052,0.000050090057,0.0011535253],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978934,0.000028771581,0.000734643,0.00054178183,0.00010087176,0.00070052483],"domain_scores_gemma":[0.9985588,0.00008287239,0.00042630653,0.0005179427,0.00006226591,0.0003518133],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00065423554,0.0003379345,0.0011679088,0.00017569047,0.00015977382,0.000043549207,0.00048663013,0.000028561968,0.0007007567],"category_scores_gemma":[0.0002483822,0.0003455881,0.00026402494,0.00072116393,0.00014598471,0.00040138242,0.00026785204,0.0002081849,0.0039902814],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039389288,0.0003579523,0.845832,0.0019146968,0.00047706763,0.000008130505,0.0032871806,0.000028667837,0.000015915144,0.006332452,0.10301506,0.038691524],"study_design_scores_gemma":[0.0005218687,0.00007472505,0.27682057,0.00039746653,0.000094160874,0.000007842906,0.00005872881,0.000053223142,0.000025577368,0.00025777865,0.72103363,0.00065441383],"about_ca_topic_score_codex":0.00019104518,"about_ca_topic_score_gemma":0.000026850072,"teacher_disagreement_score":0.62270254,"about_ca_system_score_codex":0.0001439819,"about_ca_system_score_gemma":0.000014657555,"threshold_uncertainty_score":0.9998996},"labels":[],"label_agreement":null},{"id":"W2285884689","doi":"10.3833/pdr.v2012i11.1832","title":"Pfizer Forays into ADHD Market by Exercising Option to Acquire NextWave Pharmaceuticals","year":2012,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Methylphenidate; Attention deficit hyperactivity disorder; Quarter (Canadian coin); Business; Medicine; Psychiatry","score_opus":0.1161500219915705,"score_gpt":0.45813185607138196,"score_spread":0.3419818340798115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2285884689","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08286016,0.8485997,0.012198709,0.037934504,0.00095353514,0.005700938,0.00005142848,0.00040554325,0.0112955095],"genre_scores_gemma":[0.7893259,0.16513592,0.003105648,0.037170682,0.0007462271,0.00044691152,0.00013676353,0.00013712309,0.0037948613],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972934,0.00033365324,0.00067778904,0.00042121267,0.00057298405,0.00070093066],"domain_scores_gemma":[0.99822676,0.00017781938,0.00018768362,0.0004486899,0.00017306666,0.00078597554],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0016427053,0.0003553497,0.0008612123,0.00011156937,0.00012712253,0.0000361485,0.00015643025,0.00009739865,0.008712189],"category_scores_gemma":[0.0005070096,0.00031394983,0.0002820487,0.000539039,0.000048189715,0.0007066487,0.000121921046,0.0003308375,0.0023608748],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019456871,0.0008873086,0.0030136085,0.008559803,0.00017833269,0.0000143688585,0.00039885228,0.0000011535463,0.05043336,0.00007144491,0.48568657,0.45056063],"study_design_scores_gemma":[0.0011969991,0.000051245097,0.000555321,0.0043173907,0.0010054394,0.00015399775,0.00015514449,0.00014659578,0.0026289038,0.000027085622,0.9893203,0.0004415946],"about_ca_topic_score_codex":0.000010809121,"about_ca_topic_score_gemma":2.2503339e-7,"teacher_disagreement_score":0.7064657,"about_ca_system_score_codex":0.00017166954,"about_ca_system_score_gemma":0.000044306325,"threshold_uncertainty_score":0.9999313},"labels":[],"label_agreement":null},{"id":"W2309079920","doi":"10.3833/pdr.v2014i9.2063","title":"Roche to Buy InterMune for US$8.3 B to Gain Pirfenidone for Idiopathic Pulmonary Fibrosis","year":2014,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pirfenidone; Medicine; Franchise; Idiopathic pulmonary fibrosis; Asthma; Omalizumab; Internal medicine; Business; Business administration; Lung; Immunology","score_opus":0.027396051136400222,"score_gpt":0.34447733930266766,"score_spread":0.31708128816626746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2309079920","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022781065,0.54010236,0.2250993,0.15111603,0.0038806433,0.04779825,0.0025948028,0.001049489,0.005578052],"genre_scores_gemma":[0.8820329,0.018680101,0.008274699,0.07855456,0.0031778414,0.006589393,0.00040493053,0.00022940476,0.002056182],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970912,0.00013727999,0.0009286398,0.0007603089,0.0003454781,0.0007371172],"domain_scores_gemma":[0.99772394,0.00019147796,0.00018376691,0.0005999263,0.00040004702,0.0009008669],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012880114,0.00044796153,0.0012792187,0.00016603846,0.00017171507,0.000039324714,0.0003759183,0.00010796817,0.00017247435],"category_scores_gemma":[0.0009365873,0.0003891669,0.00081539067,0.0003842029,0.000037126425,0.00013273311,0.00014796332,0.00019107258,0.00030565812],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015834693,0.0011779246,0.00024559823,0.11855963,0.00038368424,0.00004886972,0.0002485627,0.000031942927,0.2792911,0.0017757554,0.27284253,0.3095597],"study_design_scores_gemma":[0.0013632603,0.005840826,0.00031463895,0.03360889,0.0013428773,0.000117887495,0.000017473143,0.0015247572,0.007356144,0.00025311945,0.94755614,0.0007039633],"about_ca_topic_score_codex":0.000021519463,"about_ca_topic_score_gemma":0.0000015241843,"teacher_disagreement_score":0.8592518,"about_ca_system_score_codex":0.00014794702,"about_ca_system_score_gemma":0.00010316624,"threshold_uncertainty_score":0.999856},"labels":[],"label_agreement":null},{"id":"W2314904138","doi":"10.3833/pdr.v2011i9.1548","title":"PerkinElmer Agrees to Acquire Caliper Life Sciences for US$600 M","year":2011,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"Science, Research, and Medicine","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Calipers; Portfolio; Cash; Business; Database transaction; Quarter (Canadian coin); Marketing; Computer science; Finance; Engineering; Mechanical engineering","score_opus":0.3463556383388496,"score_gpt":0.48106812351417416,"score_spread":0.13471248517532458,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2314904138","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24000965,0.62445605,0.0006848218,0.056259524,0.0011803398,0.010822522,0.000051464413,0.00029863697,0.06623698],"genre_scores_gemma":[0.48966062,0.28409925,0.004403931,0.21303904,0.0017889629,0.0009364827,0.000018021034,0.000060756327,0.005992944],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976439,0.000066676905,0.00043705018,0.00048996677,0.0007329384,0.0006294704],"domain_scores_gemma":[0.99833584,0.000103385166,0.000080985374,0.00027804074,0.0002608084,0.0009409694],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020076635,0.00019728283,0.00062054,0.00016722766,0.00018182465,0.00001126691,0.00040832354,0.000040228504,0.0030576359],"category_scores_gemma":[0.0012573197,0.00012329189,0.00017882788,0.0007976042,0.000339276,0.00015122931,0.00007852853,0.0001304404,0.00040433553],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003427999,0.00057850423,0.046532996,0.01632329,0.00015921691,0.0000728103,0.0023815597,7.3002354e-7,0.0136551475,0.00082123495,0.75849587,0.16063581],"study_design_scores_gemma":[0.0017055713,0.0011084591,0.019049583,0.006221439,0.00035319693,0.00010283482,0.00013908936,0.000066934466,0.0046366076,0.000046841218,0.9662656,0.00030381719],"about_ca_topic_score_codex":0.000086676584,"about_ca_topic_score_gemma":0.0000037863808,"teacher_disagreement_score":0.3403568,"about_ca_system_score_codex":0.000033089684,"about_ca_system_score_gemma":0.00032368896,"threshold_uncertainty_score":0.9978537},"labels":[],"label_agreement":null},{"id":"W49293275","doi":"10.3833/pdr.v2012i2.1678","title":"Xenon and Genentech Partner to Develop Pain Therapeutics and Companion Diagnostics","year":2012,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"Anesthesia and Neurotoxicity Research","field":"Neuroscience","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Xenon; General partnership; Medicine; Medical physics; Business; Engineering ethics; Medical education; Engineering; Physics; Finance; Nuclear physics","score_opus":0.18517748887070914,"score_gpt":0.40729486210594323,"score_spread":0.2221173732352341,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W49293275","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5888492,0.3858645,0.0012357531,0.01868098,0.00015923979,0.004227924,0.00001847054,0.00018022484,0.0007837197],"genre_scores_gemma":[0.47419277,0.48791677,0.00015367447,0.03746811,0.0000642856,0.00009810601,0.0000012661247,0.000021886757,0.000083134815],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980592,0.00073642685,0.00023675183,0.0002661717,0.00027528318,0.0004261315],"domain_scores_gemma":[0.99856895,0.00085367623,0.000053536554,0.00016414856,0.000044491804,0.00031517723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012371395,0.00016062612,0.00027175678,0.000045222496,0.00013820222,0.000039313923,0.00016095143,0.000031970303,0.00005472703],"category_scores_gemma":[0.000875253,0.00012680095,0.000022357235,0.00039677243,0.000078274104,0.0001318822,0.00012529608,0.00016448575,0.00011552523],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000401624,0.00044259705,0.06730719,0.005335071,0.000020775662,0.00006176931,0.00071564905,4.9935295e-7,0.35836902,0.0026561224,0.017600939,0.5474502],"study_design_scores_gemma":[0.00019567864,0.000084285355,0.0053623323,0.0006901707,0.00004490845,0.00015758947,0.0000064135857,0.00007822588,0.12678406,0.000042194162,0.8662826,0.00027158178],"about_ca_topic_score_codex":0.0000020344564,"about_ca_topic_score_gemma":2.4161676e-7,"teacher_disagreement_score":0.8486816,"about_ca_system_score_codex":0.000013090629,"about_ca_system_score_gemma":0.000021499493,"threshold_uncertainty_score":0.5170793},"labels":[],"label_agreement":null},{"id":"W73664796","doi":"10.3833/pdr.v2013i11.1991","title":"Endo Looks to Geographic Expansion and Tax Advantages with US$1.6 B Paladin Buyout","year":2013,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Revenue; Stock (firearms); Business; Corporate tax; Offset (computer science); Irish; Footprint; Order (exchange); Emerging markets; Finance; Geography; Engineering; Tax avoidance; Double taxation; Mechanical engineering","score_opus":0.2162782767136228,"score_gpt":0.427603316892974,"score_spread":0.2113250401793512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W73664796","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.39463037,0.49548063,0.0012600092,0.09700602,0.00039451994,0.0063135982,0.00033112973,0.00015430182,0.004429416],"genre_scores_gemma":[0.54817456,0.29178223,0.0052590054,0.15089147,0.00041008476,0.00209766,0.00006477004,0.00011758138,0.0012026201],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956912,0.00029693777,0.0026952566,0.00069641875,0.0001133363,0.000506883],"domain_scores_gemma":[0.99732125,0.00039573666,0.0011844571,0.00053033116,0.00008626887,0.00048196517],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0058112713,0.00029459683,0.0013546468,0.00028172522,0.00016202503,0.00010061003,0.00026576553,0.00006975024,0.00197758],"category_scores_gemma":[0.00071521255,0.00029152707,0.00010826796,0.00027380025,0.00006422383,0.00059265795,0.00007736989,0.00018834986,0.0050373627],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000036267742,0.0003253265,0.59715366,0.031033125,0.00043736375,0.000013958707,0.0017693404,0.000052942043,0.00018349168,0.021303417,0.31871322,0.028977895],"study_design_scores_gemma":[0.0014257109,0.00024930714,0.10725811,0.005807614,0.00007079429,0.00006071253,0.00019316234,0.00033374727,0.000045132314,0.0030980927,0.8803573,0.0011002839],"about_ca_topic_score_codex":0.0010629377,"about_ca_topic_score_gemma":0.000045132456,"teacher_disagreement_score":0.56164414,"about_ca_system_score_codex":0.00009967596,"about_ca_system_score_gemma":0.000049063397,"threshold_uncertainty_score":0.9999537},"labels":[],"label_agreement":null},{"id":"W9436761","doi":"10.3833/pdr.v2011i9.1531","title":"Sanofi’s Aventis Pharma Subsidiary to Acquire Nutraceuticals Business of India’s Universal Medicare","year":2011,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Nutraceutical; Portfolio; Quarter (Canadian coin); Marketing; Finance; Medicine","score_opus":0.1334269315679914,"score_gpt":0.33087790487588586,"score_spread":0.19745097330789446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W9436761","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06785249,0.6190192,0.0013026427,0.02153996,0.0024899025,0.0036544816,0.0030361894,0.00023067788,0.28087443],"genre_scores_gemma":[0.71366584,0.2646221,0.0005725984,0.020419786,0.00024788934,0.0000907452,0.000047531692,0.000069864305,0.00026361804],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973291,0.000068887675,0.0013900574,0.00054884265,0.00007806792,0.0005850063],"domain_scores_gemma":[0.9981944,0.00008175366,0.0005428947,0.00048056262,0.00010259908,0.0005978125],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010835252,0.0003144762,0.0011577088,0.00028253847,0.00006586849,0.000018828265,0.00072085066,0.000112795446,0.012603162],"category_scores_gemma":[0.00020078536,0.00035042228,0.00029291172,0.000762057,0.00013657362,0.00033391351,0.00020959924,0.00022713827,0.0025417975],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000408995,0.0025100834,0.06552561,0.0288814,0.0018528017,0.00027334245,0.004251315,0.000012941757,0.001111723,0.56074935,0.21529813,0.11912429],"study_design_scores_gemma":[0.0012575816,0.00006690047,0.019218506,0.001318685,0.00016304938,0.00002809988,0.00002797008,0.000087608976,0.0029426499,0.005657011,0.96846384,0.0007681038],"about_ca_topic_score_codex":0.000120105935,"about_ca_topic_score_gemma":0.0000025422114,"teacher_disagreement_score":0.7531657,"about_ca_system_score_codex":0.00010258176,"about_ca_system_score_gemma":0.00008258168,"threshold_uncertainty_score":0.9998948},"labels":[],"label_agreement":null}]}